Mesenchymal stem cells from Wharton Jelly are an advanced therapy medicinal product (ATMP). Wharton jelly is a substance located in the umbilical cord, formed mainly by mucopolysaccharides (hyaluronic acid and chondroitin sulphate).

The complicated process of manufacturing the medicinal products takes places in the Laboratory of Cell Engineering of Polish Stem Cell Bank S.A based on the approval issued by the Chief Pharmaceutical Inspector.

The Polish Stem Cell Bank (PBKM – Polski Bank Komórek Macierzystych) as the only in the country owns the prestigious accreditation od AABB (American Association of Blood Banks). PBKM as the only non-governmental institution in Poland achieved the positive decision of Chief Pharmaceutical Inspector for manufacturing the unique medicinal product: mesenchymal stem cells from Wharton Jelly. It is the only cell bank in Poland which not only stores the frozen cells but according to the law, it can manufacture (grow) them especially for a Patient,  and after the approval prepares it for the transplantation. The procedure takes places in Central Laboratory of PBKM – biggest lab in Middle Europe specialising in umbilical cord blood preparation.

In November 2014 the first applications of the mesenchymal stem cells in Patients with autism and ALS (amyotrophic lateral sclerosis) took place. MSCs therapy is a great innovative, experimental method, being still at the clinical research stage, but showing very positive outcomes in Patient treatment.

Mesenchymal stem cells treatment is available as the medical experiment, focused on the delay of the disease progression through the damaged neurones regeneration, which can lead to the relieve of the disease symptoms in a Patient.

Mesenchymal stem cells have the immunosuppressive and immunomodulating effect.

It is the procedure involving the intravenous administration (sometimes other –injection into the cerebrospinal fluid, into the joint) of proper (regular, health) mesenchymal stem cells, which could possibly come from Patient, but more often come from the unrelated donor. It seems a more therapeutically favorable solution, as we avoid the possibility of application of cells which are also infected by the Patients health “problem” (if the disease entity has the genetic background).

In the adult human body, mesenchymal stem cells are localised mainly in the marrow, fat tissue, muscle tissue, blood and lungs. However, because of a very easy, non-invasive availability and the higher growth potential, mesenchymal stem cells derived from the umbilical cord seem to be the most helpful biological material for regenerative medicine, haematology, oncology and transplantation. They got isolated from the Wharton’s Jelly and been first described by doctor Thomas Wharton (1614-1673) in 1656. The International Society for Cellular Therapy (ISCT) established strict criteria which have to be met by stem cells population, to become recognised as mesenchymal stem cells.  These include expression of specific antigens, self-duplication, differentiating into bone tissue, cartilage, muscle and nerve tissues, functions facilitating engraftment of transplanted hematopoietic cells and immunomodulatory effects. Cells obtained from the Wharton’s Jelly meet the above-mentioned criteria. Furthermore, it was found that the mesenchymal stem cells from Wharton’s jelly exhibit significantly greater proliferative potential than the cells derived from the bone marrow.

 

Since November 2014 the medicinal therapeutic experiment was attended by patients with these disease entities in the field of neurology and ophthalmology:

• Treatment of autism with mesenchymal stem cells
• Treatment of Motor Neuron Disease
• Treatment of amyotrophic lateral sclerosis (ALS) with mesenchymal stem cells
• Treatment of Muscular Dystrophy with mesenchymal stem cells
• Treatment of Multiple Sclerosis with mesenchymal stem cells:
• Ataxia Treatment with mesenchymal stem cells:
• Treatment of Spinal muscular atrophy with mesenchymal stem cells:
• Treatment of optic neuropathy with mesenchymal stem cells:
• Optic nerve Hypoplasia treatment with mesenchymal stem cells:
• Treatment of Stargardt Disease with mesenchymal stem cells:
• Treatment of the Demyelinating Optic Nerve Damage with mesenchymal stem cells

 

Stem Cells Therapy for Diabetes type 1 –  Now also available therapies for Diabetics type 1.

Since January 2021 we have also resumed the qualification of Patients suffering from the Pulmonary Fibrosis. If you are looking for a Pulmonary Fibrosis Stem Cells Treatment please contact us via the contact form. 

Stem Cells Therapy for Post-Covid 19 Syndrome (with complications). 
If you are suffering from the Post COVID Syndrome with complications, you can now apply for the mesenchymal stem cells treatment (it is an experimental therapy).

Documents required for qualification:

• Hospital treatment information cards that confirm a past COVID-19
• HRCT, Gasometry, Spirometry – not older than 3 months
• Morphology, CRP, creatinine, electrolytes (current)

Many years of medical trials and research prove the safety of this treatment method. It is confirmed that cells used in this therapy do not cause neoplastic changes (cancer tissues grow). To read more about the safety and clinical trials outcomes please contact us, we will be glad to send you some papers through e-mail.

The eligibility criteria differ from the disease type, stadium, general Patient health, age and other factors. Each case is considered individually. Important is, that Patients willing to undergo a mesenchymal stem cells treatment cannot have any virus or bacterial infection because stem cells will first “repair” the changes made by the active disease (for example flu or borreliosis) rather than nerve tissues.

After Patient qualification for the  MSCs Therapy –on behalf of the Patient, Clinic applies to the  Commission of the Bioethics,  in the Medical Chambers in Czestochowa.

At this stage, patients are waiting for the approval of the application by the Commission of Bioethics.

In the case of successful application, the Patient is contacted to provide information regarding:

1. The terms of injections
2. Estimated costs of therapy (it depends on age, health and other factors)
3. Required additional testing
4. Other additional information

The staff consists of:

– Head of the administration department in the Clinic

– Members of the research team on behalf of the Polish Center for Cell Therapy and Immunotherapy:

– Members of the research team in the name of the Polish Stem Cell Bank:

– Patient Coordinators